ADMA — ADMA Biologics, Inc.

ADMA Biologics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $114.5 million, flat compared to $114.8 million in Q1 2025.
• ASCENIV Revenue: $97.5 million, up 28% year-over-year.
• BIVIGAM Revenue: $15.4 million, down 54% due to competitive pressures.
• Gross Profit: $80.8 million, with a gross margin of 71%, up from 53% in the prior year.
• Adjusted EBITDA: $59.7 million, representing 24% year-over-year growth.
• Adjusted Net Income: $40.7 million; GAAP net income was $45.3 million.
• Operating Cash Flow: Approximately $58 million generated during the quarter.
• Pro Forma Net Leverage: Below 0.5x, with $100 million in additional borrowing capacity.
• Cash and Cash Equivalents: $138 million at quarter-end.

2. Strategic Updates and Business Highlights

• ASCENIV Demand: Record levels of demand with strong metrics in new patient starts, prescriber adoption, and patient adherence.
• Plasma Centers: Successfully monetized three plasma centers, enhancing liquidity and diversifying plasma sourcing through a new third-party supplier.
• Expense Management: Actively reducing expenses to improve profitability without impacting core operations.
• R&D Initiatives: Progress on SG-001, with plans for a pre-IND submission to the FDA later in 2026, potentially representing a $300 million to $500 million market opportunity.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be in the range of $530 million to $560 million, reflecting continued ASCENIV growth but offset by competitive pressures in the standard IG space.
• Adjusted EBITDA Guidance: Projected between $265 million and $300 million.
• Adjusted Net Income Guidance: Expected to be between $170 million and $200 million.
• Long-term Guidance: Withdrawn due to uncertainty in the competitive landscape, although confidence in ASCENIV's demand fundamentals remains strong.

4. Challenges and Points of Concern

• BIVIGAM Performance: Significant revenue decline attributed to increased competition and aggressive pricing tactics from new entrants in the IG market.
• Market Dynamics: A shift in ordering patterns and inventory levels among distributors has created variability in revenue, particularly affecting BIVIGAM.
• Competitive Pressures: New entrants have led to ASP erosion of 15% to 20% in the standard IG market, impacting ADMA's pricing strategy.
• DSO Increase: Days Sales Outstanding rose to approximately 107 days, with a target to reduce to 90-105 days in the latter half of the year.

5. Notable Q&A Insights

• Competitive Dynamics: Adam Grossman noted that the competitive pressures began to intensify in early March 2026, primarily affecting BIVIGAM, while ASCENIV remains insulated.
• Utilization Trends: BIVIGAM showed signs of recovery in utilization in April, while ASCENIV's demand continues to grow robustly.
• McKesson Partnership: The partnership is expected to enhance ASCENIV's market presence and contribute to new prescribers, with early signs of increased utilization noted in April.
• Long-term Market Outlook: The IG market is projected to grow at lower single digits, a shift from previous double-digit growth, with ADMA focusing on secondary immune deficiency as a growth driver.
• SG-001 Development Timeline: Clinical trials for SG-001 could take approximately 18 months to complete once initiated, with a pre-IND meeting planned for later in 2026.

Overall, ADMA Biologics demonstrated strong financial performance in Q1 2026, particularly with ASCENIV, while facing challenges in the competitive landscape for BIVIGAM. The company remains optimistic about its growth trajectory and strategic initiatives moving forward.